Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)

Exclusion Criteria

• •Has a history of recent or recurrent Gram-positive organism UTI suggesting colonization, or participant with UTI that shows or suspects the presence of a Gram-positive organism only
• •Has a history of any moderate or severe hypersensitivity or allergic reaction to any Beta-lactam antibacterial including cephalosporins, carbapenems and penicillins, or tazobactam
• •Has a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to study drug with the exception of an antibacterial with Gram-positive activity only (vancomycin, linezolid, daptomycin and teicoplanin)
• •Is receiving probenecid
• •Is currently receiving bladder infusions with topical urinary antiseptics or antibacterial agents
• •Has received any amount of potentially therapeutic antibacterial therapy after collection of the pretreatment baseline urine culture and before administration of the first dose of study drug.
• •Has received any dose of a potentially therapeutic antibacterial agent for the treatment of the current UTI within 48 hours before the pretreatment baseline urine is obtained
• •Intractable urinary infection at baseline that would require more than 7 days of study drug
• •Has complete, permanent obstruction of the urinary tract.
• •Has confirmed fungal urinary tract infection at time of randomization (with ≥ 10\^3 fungal colony forming units /mL)
• •Has permanent indwelling bladder catheter or urinary stent including nephrostomy
• •Has suspected or confirmed perinephric or intrarenal abscess
• •Has suspected or confirmed prostatitis, urethritis, or epididymitis
• •Has ileal loop or known vesico-ureteral reflux
• •Severe impairment of renal function including an estimated CrCl \< 30 mL/min, requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (\< 20 mL/hr urine output over 24 hours)
• •Has urinary catheter that is not scheduled to be removed before the end of therapy
• •Has any rapidly progressing disease or immediately life-threatening illness including acute hepatic failure, respiratory failure, and septic shock
• •Has an immunocompromising condition (i.e., AIDS, hematological malignancy, or bone marrow transplantation, or immunosuppressive therapy) or is receiving ≥ 40 mg of prednisone per day administered continuously for \> 14 days prior to study start
• •Has participated in any clinical study of an investigational product within 30 days prior to the first dose of study drug
• •Has previously participated in any study of ceftolozane or MK-7625A.